THBS2 has recently been proposed by Kozumi et al. as a potential biomarker for advanced fibrosis and NASH, as it has been found to be significantly overexpressed in patients with fibrosis, and its circulating protein product TSP-2 (thrombospondin 2) was shown to be an independent predictor of NASH [258]. The gene discussed is THBS2; the disease is metabolic dysfunction-associated steatohepatitis.